International Assets Investment Management LLC Acquires Shares of 58,548 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

International Assets Investment Management LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 58,548 shares of the specialty pharmaceutical company's stock, valued at approximately $7,201,000. International Assets Investment Management LLC owned approximately 0.09% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $611,000. Commonwealth Equity Services LLC grew its position in Jazz Pharmaceuticals by 10.6% in the third quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company's stock worth $1,304,000 after acquiring an additional 962 shares in the last quarter. Forsta AP Fonden increased its stake in Jazz Pharmaceuticals by 15.2% in the third quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company's stock valued at $2,848,000 after acquiring an additional 2,900 shares during the last quarter. Strs Ohio raised its position in Jazz Pharmaceuticals by 4.4% during the third quarter. Strs Ohio now owns 14,119 shares of the specialty pharmaceutical company's stock valued at $1,827,000 after purchasing an additional 593 shares in the last quarter. Finally, Advisor Partners II LLC bought a new stake in Jazz Pharmaceuticals during the third quarter worth about $231,000. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the business's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 5,000 shares of the company's stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.2 %

NASDAQ:JAZZ traded up $1.36 during mid-day trading on Tuesday, reaching $111.21. 841,956 shares of the company's stock traded hands, compared to its average volume of 617,356. Jazz Pharmaceuticals plc has a 12-month low of $103.01 and a 12-month high of $146.70. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The company has a 50 day moving average price of $115.56 and a 200-day moving average price of $120.62. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 1.53 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday. Stifel Nicolaus lifted their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a research note on Friday, March 15th. Piper Sandler upped their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Truist Financial reiterated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Finally, JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $192.75.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.